TrialAnnals of oncology : official journal of the European Society for Medical Oncology2024

Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01).

C Saura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.